Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment
Abstract
:1. Introduction
2. Methods
2.1. Participants
2.2. Neuropsychological Assessments
2.3. [18F]-Florbetaben PET Image Acquisition and Analysis
2.4. Conditional Probability (CP) Calculations and Statistical Analyses
3. Results
3.1. Demographic and Clinical Characteristics
3.2. Neuropsychological Assessment
3.3. CP Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bloom, G.S. Amyloid-β and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurol. 2014, 71, 505–508. [Google Scholar] [CrossRef] [Green Version]
- Liu, R.M. Aging, Cellular Senescence, and Alzheimer’s Disease. Int. J. Mol. Sci. 2022, 23, 1989. [Google Scholar] [CrossRef] [PubMed]
- Jack, C.R., Jr.; Knopman, D.S.; Jagust, W.J.; Shaw, L.M.; Aisen, P.S.; Weiner, M.W.; Petersen, R.C.; Trojanowski, J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010, 9, 119–128. [Google Scholar] [CrossRef] [Green Version]
- Perrin, R.J.; Fagan, A.M.; Holtzman, D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 2009, 461, 916–922. [Google Scholar] [CrossRef]
- Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259. [Google Scholar] [CrossRef]
- Thal, D.R.; Rub, U.; Orantes, M.; Braak, H. Phases of A β-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58, 1791–1800. [Google Scholar] [CrossRef] [PubMed]
- Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergstrom, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55, 306–319. [Google Scholar] [CrossRef] [PubMed]
- Bateman, R.J.; Xiong, C.; Benzinger, T.L.; Fagan, A.M.; Goate, A.; Fox, N.C.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazey, T.M.; et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 2012, 367, 795–804. [Google Scholar] [CrossRef] [Green Version]
- Fodero-Tavoletti, M.T.; Brockschnieder, D.; Villemagne, V.L.; Martin, L.; Connor, A.R.; Thiele, A.; Berndt, M.; McLean, C.A.; Krause, S.; Rowe, C.C.; et al. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl. Med. Biol. 2012, 39, 1042–1048. [Google Scholar] [CrossRef]
- Sepulcre, J.; Sabuncu, M.R.; Becker, A.; Sperling, R.; Johnson, K.A. In vivo characterization of the early states of the amyloid-β network. Brain 2013, 136, 2239–2252. [Google Scholar] [CrossRef]
- Villain, N.; Chetelat, G.; Grassiot, B.; Bourgeat, P.; Jones, G.; Ellis, K.A.; Ames, D.; Martins, R.N.; Eustache, F.; Salvado, O.; et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: A voxelwise PiB-PET longitudinal study. Brain 2012, 135, 2126–2139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grothe, M.J.; Barthel, H.; Sepulcre, J.; Dyrba, M.; Sabri, O.; Teipel, S.J. In vivo staging of regional amyloid deposition. Neurology 2017, 89, 2031–2038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, Y.; Li, C.; Yang, H.; Wu, Y.; Xu, B.; Zhang, J.; Wang, R. (18)F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients. Front. Neurosci. 2020, 14, 745. [Google Scholar] [CrossRef]
- Piramal Imaging Limited, N. Summary of Product Characteristics; Piramal Imaging Limited: Cambridge, UK, 2014. [Google Scholar]
- Sabri, O.; Seibyl, J.; Rowe, C.; Barthel, H. β-amyloid imaging with florbetaben. Clin. Transl. Imaging 2015, 3, 13–26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sabri, O.; Sabbagh, M.N.; Seibyl, J.; Barthel, H.; Akatsu, H.; Ouchi, Y.; Senda, K.; Murayama, S.; Ishii, K.; Takao, M.; et al. Florbetaben PET imaging to detect amyloid β plaques in Alzheimer’s disease: Phase 3 study. Alzheimers Dement. 2015, 11, 964–974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barthel, H.; Luthardt, J.; Becker, G.; Patt, M.; Hammerstein, E.; Hartwig, K.; Eggers, B.; Sattler, B.; Schildan, A.; Hesse, S.; et al. Individualized quantification of brain β-amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 1702–1714. [Google Scholar] [CrossRef]
- Barthel, H.; Gertz, H.-J.; Dresel, S.; Peters, O.; Bartenstein, P.; Buerger, K.; Hiemeyer, F.; Wittemer-Rump, S.M.; Seibyl, J.; Reininger, C.; et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol. 2011, 10, 424–435. [Google Scholar] [CrossRef]
- Jennings, D.; Seibyl, J.; Sabbagh, M.; Lai, F.; Hopkins, W.; Bullich, S.; Gimenez, M.; Reininger, C.; Putz, B.; Stephens, A.; et al. Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology 2015, 84, 500–507. [Google Scholar] [CrossRef]
- Kim, S.E.; Lee, B.; Park, S.; Cho, S.H.; Kim, S.J.; Kim, Y.; Jang, H.; Jeong, J.H.; Yoon, S.J.; Park, K.W.; et al. Clinical significance of focal ss-amyloid deposition measured by (18)F-flutemetamol PET. Alzheimers Res. Ther. 2020, 12, 6. [Google Scholar] [CrossRef]
- Josephs, K.A.; Murray, M.E.; Whitwell, J.L.; Tosakulwong, N.; Weigand, S.D.; Petrucelli, L.; Liesinger, A.M.; Petersen, R.C.; Parisi, J.E.; Dickson, D.W. Updated TDP-43 in Alzheimer’s disease staging scheme. Acta Neuropathol. 2016, 131, 571–585. [Google Scholar] [CrossRef]
- Cho, H.; Lee, H.S.; Choi, J.Y.; Lee, J.H.; Ryu, Y.H.; Lee, M.S.; Lyoo, C.H. Predicted sequence of cortical tau and amyloid-β deposition in Alzheimer disease spectrum. Neurobiol. Aging 2018, 68, 76–84. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Basak, J.M.; Holtzman, D.M. The role of apolipoprotein E in Alzheimer’s disease. Neuron 2009, 63, 287–303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kang, Y.; Na, D.L. Seoul Neuropsychological Screening Battery (SNSB); Human Brain Research & Consulting Co.: Incheon, Korea, 2003. [Google Scholar]
- Ahn, H.J.; Chin, J.; Park, A.; Lee, B.H.; Suh, M.K.; Seo, S.W.; Na, D.L. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): A useful tool for assessing and monitoring cognitive impairments in dementia patients. J. Korean Med. Sci. 2010, 25, 1071–1076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Petersen, R.C.; Smith, G.E.; Waring, S.C.; Ivnik, R.J.; Tangalos, E.G.; Kokmen, E. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 1999, 56, 303–308. [Google Scholar] [CrossRef]
- Naik, M.; Nygaard, H.A. Diagnosing dementia-ICD-10 not so bad after all: A comparison between dementia criteria according to DSM-IV and ICD-10. Int. J. Geriatr. Psychiatry 2008, 23, 279–282. [Google Scholar] [CrossRef]
- Nelson, P.T.; Abner, E.L.; Scheff, S.W.; Schmitt, F.A.; Kryscio, R.J.; Jicha, G.A.; Smith, C.D.; Patel, E.; Markesbery, W.R. Alzheimer’s-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci. Lett. 2009, 450, 336–339. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fantoni, E.; Collij, L.; Lopes Alves, I.; Buckley, C.; Farrar, G.; AMYPAD consortium. The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging. J. Nucl. Med. 2020, 61, 166–171. [Google Scholar] [CrossRef]
- Palmqvist, S.; Scholl, M.; Strandberg, O.; Mattsson, N.; Stomrud, E.; Zetterberg, H.; Blennow, K.; Landau, S.; Jagust, W.; Hansson, O. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 2017, 8, 1214. [Google Scholar] [CrossRef] [Green Version]
- Sakr, F.A.; Grothe, M.J.; Cavedo, E.; Jelistratova, I.; Habert, M.O.; Dyrba, M.; Gonzalez-Escamilla, G.; Bertin, H.; Locatelli, M.; Lehericy, S.; et al. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: The INSIGHT-preAD study. Alzheimers Res. Ther. 2019, 11, 15. [Google Scholar] [CrossRef]
- Syed, Y.Y.; Deeks, E. [(18)F]Florbetaben: A review in beta-amyloid PET imaging in cognitive impairment. CNS Drugs 2015, 29, 605–613. [Google Scholar] [CrossRef]
- Roberts, R.O.; Aakre, J.A.; Kremers, W.K.; Vassilaki, M.; Knopman, D.S.; Mielke, M.M.; Alhurani, R.; Geda, Y.E.; Machulda, M.M.; Coloma, P.; et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurol. 2018, 75, 970–979. [Google Scholar] [CrossRef] [PubMed]
- Carapelle, E.; Mundi, C.; Cassano, T.; Avolio, C. Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease. Int. J. Mol. Sci. 2020, 21, 6279. [Google Scholar] [CrossRef] [PubMed]
- Farrell, M.E.; Chen, X.; Rundle, M.M.; Chan, M.Y.; Wig, G.S.; Park, D.C. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology 2018, 91, e1809–e1821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Landau, S.M.; Horng, A.; Jagust, W.J.; Alzheimer’s Disease Neuroimaging, I. Memory decline accompanies subthreshold amyloid accumulation. Neurology 2018, 90, e1452–e1460. [Google Scholar] [CrossRef]
- Bischof, G.N.; Jacobs, H.I.L. Subthreshold amyloid and its biological and clinical meaning: Long way ahead. Neurology 2019, 93, 72–79. [Google Scholar] [CrossRef]
- Leal, S.L.; Lockhart, S.N.; Maass, A.; Bell, R.K.; Jagust, W.J. Subthreshold Amyloid Predicts Tau Deposition in Aging. J. Neurosci. 2018, 38, 4482–4489. [Google Scholar] [CrossRef] [Green Version]
CN | MCI | Dementia | ||
---|---|---|---|---|
Population | Number (%) | 9 (15.5) | 32 (55.2) | 17 (29.3) |
Sex, Female (%) | 6 (66.7) | 16 (50) | 14 (82.3) | |
Age (SD) *, y | 73.8 (4.5) | 77.5 (6.5) | 81.9 (6.6) | |
Education (SD), y | 5.2 (4.9) | 10.8 (5.6) | 8.8(3.9) | |
Symptom duration, (SD), m * | 12.2 (7.5) | 23.5 (17.8) | 30.3 (20.1) | |
Global cognition | MMSE (SD) * + | 25.9 (3.5) | 25.3 (4.0) | 19.1 (4.9) |
CDR (SD) * + | 0.3 (0.3) | 0.5 (0.1) | 0.7 (0.3) | |
CDR-SOB (SD) * + | 2.0 (0.7) | 3.2 (0.7) | 4.2 (0.7) | |
Vascular risk factors | DM, n (%) | 1 (11.1) | 10 (31.3) | 6 (35.3) |
HTN, n (%) | 5 (55.6) | 18 (56.3) | 7 (41.1) | |
Dyslipidemia, n (%) | 4 (44.4) | 5 (25.0) | 7 (41.1) | |
Genetics | ApoE ε4 carrier, n (%) | 3 (33.3) | 13 (44.8) | 5 (29.4) |
Domain | CN | MCI | AD | |
---|---|---|---|---|
Attention | DS-F | 0.4 ± 0.8 | 0.0 ± 1.0 | −0.5 ± 1.2 |
DS-B | −0.2 ± 0.9 | 0.0 ± 1.1 | −0.6 ± 1.1 | |
Language | K-BNT * | 0.3 ± 0.7 | −1.3 ± 1.8 | −2.1 ± 2.0 |
Visuospatial | RCFT copying | −0.8 ± 1.6 | −0.4 ± 1.6 | −2.0 ± 3.0 |
Memory | SVLT, immediate * | 0.1 ± 0.9 | −0.8 ± 0.9 | −1.6 ± 1.0 |
SVLT, delayed * | 0.1 ± 0.9 | −1.6 ± 0.9 | −2.7 ± 1.6 | |
SVLT, recognition * | 0.4 ± 1.2 | −1.2 ± 1.4 | −2.2 ± 1.6 | |
RCFT, immediate * | −0.2 ± 1.0 | −1.1 ± 0.8 | −1.7 ± 0.5 | |
RCFT, delayed * | −0.0 ± 0.9 | −1.2 ± 0.7 | −1.7 ± 0.6 | |
RCFT, recognition | −0.5 ± 0.9 | −0.8 ± 1.0 | −1.6 ± 1.7 | |
Frontal/executive | COWAT, Animal * | 0.3 ± 1.4 | −1.0 ± 1.1 | −1.5 ± 1.2 |
COWAT, Supermarket * | 0.1 ± 1.5 | −0.5 ± 0.9 | −1.4 ± 0.7 | |
COWAT, Phonemic * | 0.3 ± 1.5 | −0.3 ± 1.0 | −1.2 ± 0.9 | |
K-COWAT-CR | −0.7 ± 1.3 | −1.2 ± 1.0 | −1.7 ± 1.1 |
ROIs | Lateral Temporal | Frontal | Parietal | Posterior Cingulate/ Precuneus | Occipital | Anterior Striatum |
---|---|---|---|---|---|---|
Number | 24 | 9 | 21 | 41 | 8 | 2 |
Frequency (%) | 40 | 15 | 35 | 68.3 | 13.3 | 3.3 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chung, S.-e.; Kim, H.-J.; Jo, S.; Lee, S.; Lee, Y.; Roh, J.H.; Lee, J.-H. Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. Diagnostics 2022, 12, 1357. https://doi.org/10.3390/diagnostics12061357
Chung S-e, Kim H-J, Jo S, Lee S, Lee Y, Roh JH, Lee J-H. Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. Diagnostics. 2022; 12(6):1357. https://doi.org/10.3390/diagnostics12061357
Chicago/Turabian StyleChung, Sung-eun, Hyung-Ji Kim, Sungyang Jo, Sunju Lee, Yoojin Lee, Jee Hoon Roh, and Jae-Hong Lee. 2022. "Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment" Diagnostics 12, no. 6: 1357. https://doi.org/10.3390/diagnostics12061357